| Patient | Julius Caesar |
|---|---|
| Date of birth | 1972-07-12 |
| Identifiers | MRN HR-AC001-SYN; SSN (made up) 000-01-6022 |
| Document date | 2026-09-15 |
| Author | Lucius Fairbanks-Okonkwo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Four-week review of levetiracetam, blood pressure, and the rhythm monitor. [S]
Julius Caesar returns four weeks after starting levetiracetam, atorvastatin, and aspirin. He has had no seizure, spell, or confused awakening. He was more irritable than usual in the first week, which has passed; he is not low in mood and has no thoughts of self-harm. His cold from last week has gone. He has no muscle aches, bruising, or bleeding. His home blood pressure readings over two weeks average 134/84 mmHg. The second rhythm monitor, removed yesterday, showed sinus rhythm throughout. The home sleep test showed no sleep apnea. He is not driving and has a riding companion at weekends. [S]
| Element | Detail |
|---|---|
| Seizures | None since levetiracetam was started |
| Side effects | Irritability in the first week, now gone |
| Home blood pressure | Average 134/84 mmHg over two weeks |
| Monitor and sleep test | No atrial fibrillation; no sleep apnea |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Well; cold resolved |
| Musculoskeletal | Negative | No muscle aches |
| Neurological | Negative | No spell, weakness, numbness, or speech change |
| Psychiatric | Negative | Irritability settled; mood steady |
| Hematologic | Negative | No bruising or bleeding |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Lisinopril 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth each morning | Oral route | 2026-08-04 | active | S |
| Levetiracetam 500 mg oral tablet, one tablet by mouth twice daily | 500 mg twice daily, morning and evening | Oral route | 2026-08-18 | active | S |
| Atorvastatin 80 mg oral tablet, one tablet by mouth at bedtime | One tablet by mouth at bedtime | Oral route | 2026-08-18 | active | S |
| Aspirin 81 mg delayed-release tablet, one tablet by mouth daily | One tablet by mouth daily with food | Oral route | 2026-08-18 | active | S |
| Acetaminophen 500 mg oral tablet, one or two tablets by mouth every 6 hours as needed for fever or sore throat (no more than 3 g a day) | One or two tablets every 6 hours as needed, at most 3 g a day, for up to a week | Oral route | 2026-09-08 to 2026-09-14 | completed | S |
| Amlodipine 5 mg oral tablet, one tablet by mouth daily | One tablet by mouth each morning | Oral route | 2026-09-15 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-09-15 | Body height | 182 | cm | S |
| 2026-09-15 | Body weight | 75.6 | kg | S |
| 2026-09-15 | Body mass index (BMI) [Ratio] | 22.8 | kg/m2 | S |
| 2026-09-15 | Systolic blood pressure | 136 | mm[Hg] | S |
| 2026-09-15 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 2026-09-15 | Heart rate | 68 | /min | S |
| 2026-09-15 | Respiratory rate | 14 | /min | S |
| 2026-09-15 | Body temperature | 36.6 | Cel | S |
| 2026-09-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-09-15 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-09-15 | Total score [MoCA] | 28 | {score} | S |
Vital signs recorded on 2026-09-15; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Cardiovascular | Regular rhythm; blood pressure 136/84 mmHg |
| Neurological | No focal deficit; normal gait |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Recurrent transient episodes of collapse: six days ago a witnessed collapse with stiffening and jerking of both arms for about a minute, a bitten tongue, and about twenty minutes of confusion, after a rising strange feeling and dizziness; two briefer spells of staring and unresponsiveness in the past eighteen months; cause not yet known (seizure, convulsive syncope, or transient ischemic attack) | resolved | confirmed | R56.9 | S — Synthetic presenting problem anchored to the documented accounts of falling attacks and fainting fits; it resolves when the cause is found. |
| Hypertension, stage 2: 152/94 and 148/92 mmHg today; told of high blood pressure about three years ago and never treated | active | confirmed | I10 | S — Synthetic vascular risk factor; no blood pressure from his lifetime is known. |
| Hyperlipidemia: LDL 158 mg/dL, triglycerides 170 mg/dL, HDL 44 mg/dL | active | confirmed | E78.5 | S — Synthetic vascular risk factor; no lipid value from his lifetime is known. |
| Focal epilepsy with a structural vascular cause: focal impaired-awareness seizures with automatisms, one evolving to a bilateral tonic-clonic seizure, arising from a chronic left temporal cortical infarct, with left temporal sharp waves on EEG | active | confirmed | G40.209 | S — Synthetic modern diagnosis anchored to the documented falling attacks; the ILAE 2017 seizure types and a structural cause are chosen for teaching and make no claim about what he had. |
| Chronic left posterior temporal cortical infarct, not recognized before the seizures, with moderate small-vessel white matter disease and a non-stenotic left carotid plaque; no residual deficit | active | confirmed | I69.398 | S — Synthetic modern finding anchored to the retrospective cerebrovascular hypothesis; it makes no claim about his real brain. |
| Acute viral upper respiratory infection with low-grade fever and poor sleep, three weeks after starting levetiracetam; rapid COVID-19 and influenza tests negative; resolved | resolved | confirmed | J06.9 | S — Synthetic intercurrent illness, chosen to teach cold-remedy choices with hypertension, aspirin, and an antiseizure medicine, and sleep loss as a seizure trigger; it echoes no documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (target below 130/80 mmHg) | Every visit | Completed today | 136/84 mmHg; home average 134/84 mmHg; amlodipine added |
| Self-management | Home blood pressure monitoring | Daily while treatment is adjusted | Completed today | Two weeks of stored readings reviewed |
| Imaging | Ambulatory rhythm monitoring for atrial fibrillation | At least 30 days within six months of the event | Completed today | More than 40 days in all; no atrial fibrillation |
| Examination | Sleep apnea evaluation | Consider after any stroke | Completed today | Home sleep test: apnea-hypopnea index 4 per hour; no sleep apnea |
| Survey | Depression screen (PHQ-9) | At the first visit after the event, then periodically | Completed today | 4; item 9 scored 0 |
| Survey | Cognitive screen (MoCA) | In the first year after a stroke | Completed today | 28 of 30 |
| Laboratory | Lipid panel after starting a statin | 4 to 12 weeks after starting | Due | At the ten-week visit |
| Medication safety | Statin tolerance | Every visit | Completed today | No muscle aches |
| Medication safety | Antithrombotic adherence and bleeding | Every visit | Completed today | Aspirin taken daily; no bruising or bleeding |
| Medication safety | Antiseizure medicine: seizures, adherence, and side effects | Every visit | Completed today | No seizure; irritability in the first week only; no missed doses |
| Examination | Fall risk | Every visit | Completed today | No falls |
| Examination | Weight and BMI | Every visit | Completed today | 75.6 kg; BMI 22.8 |
| Self-management | Tobacco, alcohol, physical activity, and diet | Every visit | Completed today | Diet changes kept up; walking daily; alcohol unchanged |
| Self-management | Seizure safety and driving | Every visit | Completed today | Not driving; riding only with a companion; seizure-free for four weeks |
Goal progress:
Guideline basis: Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy (2018); 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack (2021); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, stroke and transient ischemic attack, hypertension, and hyperlipidemia monographs (2026)
Follow-up: Adult preventive visit in three weeks; ten-week chronic-care review with the lipid panel. Next scheduled visit 2026-10-06: adult preventive visit. [S]